title: [Study on antitumor effect and mechanism of aloe polysaccharides].
abstract: OBJECTIVE
  To study the antitumor activity and mechanism of aloe polysaccharides (AP).
  
  
  METHODS
  AP was administered i.p. or i.v. to Sarcoma 180(S180) bearing mice or Hepatoma22(H22) bearing mice solely or combining with CTX, FU and ADM respectively. 10 days later, for S180 mice, the blood was analyzed, the tumor was peeled off and weighed, and the spleen index, thymus index was calculated. For H22 bearing mice, the survival rate was observed or the IL-2, TNF content in serum was tested.
  
  
  RESULTS
  25 mg/kg.d or 50 mg/kg.d AP group could evidently reduce the tumor weight of S180 bearing mice and prolong the survival time of H22 bearing mice. AP also could improve the antitumor effects of CTX, ADM, FU, and lessen the chemotherapy side-effects. Furthermore, AP could improve the level of IL-2, TNF in the serum of mice bearing S180 or H22.
  
  
  CONCLUSIONS
  AP has the effects of antitumor, enhancing the antitumor activity of chemotherapy drugs and lessening their side-effects. This effect was possibly derived from inducing IL-2 and TNF producing in body and improving the immunity activity.
authors.affiliation: Guangzhou University of TCM, Guangzhou 510405.
authors.forename: Z
authors.initials: Z
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: Z
authors.initials: Z
authors.lastname: Huang
authors.forename: S
authors.initials: S
authors.lastname: Zhong
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.forename: L
authors.initials: L
authors.lastname: Yu
mesh_terms: D000504:Aloe; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D007376:Interleukin-2 / Q000097:blood; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D051379:Mice; D011134:Polysaccharides / Q000494:pharmacology* / Q000627:therapeutic use; D012510:Sarcoma 180 / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D007376:Interleukin-2; D011134:Polysaccharides; D014409:Tumor Necrosis Factor-alpha